Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy–related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT

The local ethics committee approved the study (PV5292) and all women gave their written informed consent. Women with breast cancer were prospectively recruited between October 2016 and October 2017 (Fig. 1). The treatment strategy was decided by an interdisciplinary tumor board as part of clinical routine. Subsequently, patients were either treated with epirubicin-based chemotherapy followed by radiotherapy (group 1) or with left-sided radiotherapy (group 2). Patients were not randomized to the treatment strategies of group 1 or group 2. Group 1 included 39 patients (age: 51 ± 11 years, range 30–75 years) and one subject was excluded due to claustrophobia at baseline CMR (Fig. 1). Chemotherapy consisted of 4 cycles of epirubicin (90 mg/m²) combined with cyclophosphamide (600 mg/m²) and 12 cycles of paclitaxel (80 mg/m²) according to current guidelines [2]. Five group 1 patients (13%) additionally received trastuzumab due to human epidermal growth factor receptor 2 positive (HER2 +) status. Chemotherapy lasted for 5 ± 1 months and follow-up 1 (FU1) CMR was performed at 2 ± 2 weeks after completion (Fig. 2). Subsequently, 18 group 1 patients (46%) underwent left-sided radiotherapy, whereas 21 (54%) obtained right-sided radiotherapy. Surgery was either performed before (n = 15, 38%) or after chemotherapy (n = 24, 62%). FU2 CMR was acquired in group 1 at 13 ± 2 months after BL CMR.

Group 2 included 27 women (age: 56 ± 14 years, range 28–82 years) with left-sided breast cancer, who were treated with initial surgery followed by left-sided radiotherapy lasting for 1.2 ± 0.4 months (Fig. 2). Whole breast radiation was performed using a linear accelerator (Varian TrueBeam®, Varian Medical Systems). Three-dimensional tangential treatment plans with a “field-in-field” technique were established to minimize the heart dose [9]. A deep inspiration breath-hold technique was applied to reduce the heart radiation dose. Respiratory motion was monitored using the Varian respiratory gating system and the patient was instructed to take a deep breath in and hold it. The treatment beam was stopped when the breathing signal dropped outside a defined threshold for the respiratory motion of the heart [10]. The total whole-breast radiation dose was 48 ± 4 Gy and the mean cardiac dose was 2 ± 2 Gy. FU1 CMR was acquired at 1 ± 2 weeks after completion and FU2 CMR was obtained 13 ± 1 months after BL CMR. Blood samples were drawn immediately before each CMR.

CMR was performed on a 3.0-T scanner (Ingenia, Philips Medical Systems). The CMR protocol included a cine short-axis stack for LV volumes, mass, and function assessment using a standard steady-state free-precession (SSFP) sequence. T2 mapping was performed using a free-breathing navigator-gated black-blood prepared gradient and spin-echo (GraSE) hybrid sequence in three short-axis slices (basal, midventricular, and apical) [11]. T1 mapping was performed using a 5 s(3 s)3 s MOLLI sequence with typical imaging parameters: voxel size 2 × 2 × 10 mm³, echo time = 0.7 ms, time to repetition = 2.3 ms, partial echo factor = 0.8, flip angle = 35°, SENSE factor = 2, linear phase encoding, ten start-up cycles to approach steady-state prior to imaging, typical effective inversion times between 134 and 5500 ms [16]. Ten minutes after injection of 0.15 mmol/kg gadoterate meglumine (Dotarem®, Guerbet), end-diastolic late gadolinium enhancement (LGE) images were acquired using phase-sensitive inversion recovery (PSIR) sequences in short-axis and two-, three-, and four-chamber views [12]. Details are in Supplemental Material.

Two investigators (M.A. and S.S.) independently and blindly analyzed each CMR in random order using CVi42 software (Circle Cardiovascular Imaging Inc). Parameters were indexed to the body surface area (BSA). Evaluation of LV and right ventricular (RV) volumes and LV mass was performed in standard fashion [13]. To measure global native T1 and T2 relaxation times and ECV, corresponding short-axis maps were used to carefully delineate endo- and epicardial contours with 10% endo- and epicardial offsets to avoid contamination. The presence of LGE was visually analyzed [13].

Myocardial strain was analyzed on cine CMR images using Segment feature-tracking software version 2.1.R.6108 (Medviso) [14]. In short, this software analyzes myocardial strain by computing interframe deformation fields using an endocardial tracking strategy based on non-rigid image registration [14]. Global peak systolic LV longitudinal (GLS) and radial strain (GRS) were measured on 3 long-axis cine series, whereas circumferential strain (GCS) was measured on three short-axis cine series. Endo- and epicardial contours were manually delineated on end-diastolic images and were then automatically propagated by the software throughout the cardiac cycle generating myocardial strain [14].

Presence of cancer therapy–related cardiac dysfunction (CTRCD) was defined as a decline in LVEF of at least 10 to < 55% or a > 15% GLS change at FU2 CMR [3, 15].

Patients with epirubicin-based chemotherapy had higher weight, body mass index (BMI), and body surface area (BSA) compared to patients with left-sided radiotherapy (Table 1). Cancer stage is given for both groups in Table 1. There were no differences regarding cardiovascular risk factors and medication. No patient had known heart failure. High sensitive troponin T and NT-proBNP revealed no cardiac injury at baseline (Table 1).

High sensitive troponin T increased after epirubicin-based chemotherapy from 5 ± 4 to 8 ± 4 pg/ml (p = 0.04) and remained increased at FU2 with 8 ± 11 pg/ml (Table 2). NT-proBNP was unchanged from baseline to FU1 and FU2. Hematocrit and hemoglobin decreased at FU1 and then normalized at FU2. T1 and T2 increased at FU1 to 1293 ± 34 ms and 48 ± 3 ms respectively, compared to baseline with 1244 ± 29 ms (p < 0.001) and 45 ± 3 ms (p < 0.001) respectively, indicating the presence of myocardial edema (Table 2, Fig. 3). At FU2, T1 and T2 returned to baseline. Global longitudinal and circumferential strains were reduced at FU1 (p = 0.01 for GLS; p = 0.03 for GCS) and FU2 (p = 0.01 for both) with less negative strain values of − 17 ± 2% and − 17 ± 3% compared to baseline with − 18 ± 2% and − 18 ± 2%, respectively (Table 2), indicating reduced LV contractility. In contrast, LV ejection fraction was unchanged throughout (Table 2). LV, LA, and RV volumes decreased at FU1, indicating volume depletion following chemotherapy and LV and LA volumes normalized at FU2. No LGE was present at baseline and FU2, indicating the absence of focal myocardial fibrosis. ECV was normal at both time points with 28 ± 2% and 29 ± 2%, respectively (p = 0.52), excluding diffuse myocardial fibrosis. There was no indication that trastuzumab had additional cardiotoxic effects (Table S1). Laboratory and mapping parameters, ejection fraction, and myocardial strain in group 1 patients without (n = 34) and with trastuzumab treatment (n = 5) were similar at all times.

High sensitive troponin T slightly increased after left-sided radiotherapy to 6 ± 3 pg/ml at FU1 (p < 0.04) and normalized at FU2 (Table 3). All other laboratory parameters were unchanged at FU1 and FU2. Mean T1 and T2 remained constant at FU1, indicating the absence of myocardial edema (Table 3, Fig. 3). This was paralleled by normal LV function measured by ejection fraction and myocardial strain (Table 3). A slight reduction in LV and RV volumes was observed at FU1 and FU2. No focal or diffuse myocardial fibrosis was observed by LGE or ECV.

CTRCD occurred at FU2 in 8 of 39 patients (20%) after epirubicin-based chemotherapy and in one of 27 patients (4%) after left-sided radiotherapy, resulting in a total number of 9 of 66 patients (14%) with CTRCD. High sensitive troponin T and T1 and T2 increased in both groups at FU1 and normalized at FU2 (Table 4). LVEF was reduced at FU2 in patients with CTRCD according to the definition of this condition, whereas all strain parameters were already reduced at FU1 and remained reduced at FU2. LV and RV volume reduction typically occurred in both patient groups at FU1 and mostly normalized at FU2.

ROC analysis revealed that T1 and GCS at FU1 were the best single parameters to predict CTRCD at FU2 with an AUC of 0.712 (p = 0.005) and 0.712 (p = 0.07), respectively (Table 5, Fig. 4a). T1 resulted in excellent sensitivity of 100% (66–100%), but low specificity of 44% (31–58%). Conversely, GCS resulted in an acceptable sensitivity of 67% (30–93%) and specificity of 75% (61–85%). Interestingly, blood parameters of myocardial injury such as high sensitive troponin T and NT-proBNP had low AUC (Table 5). T2 had the lowest AUC of 0.513 of all parameters to predict CTRCD. The combined use of T1 as a parameter with excellent sensitivity with a parameter with higher specificity revealed that the combined use of T1 > 1262 ms and reduced LVEF ≤ 60% following breast cancer treatment at FU1 resulted in an improved AUC = 0.810. This combined use resulted in high sensitivity of 78% (44–95%) and high specificity of 84% (72–92%). The combined use of T1 and GRS or T1 and GCS also improved the AUC to 0.800 and 0.762, respectively. Other combinations of parameters were inferior to the single use of T1 (Table 5, Fig. 4).

Galán-Arriola et al recently showed in an animal study that increased T2 is the earliest imaging marker of doxorubicin-related cardiotoxicity [8]. T2 increase was related to intracardiomyocyte edema, which occurred as early as 6 weeks after initiation of chemotherapy in pigs. This study showed that the T2 increase was not paralleled by a decrease of ejection fraction and discontinuing chemotherapy upon detection of T2 prolongation halted LV dysfunction development, demonstrating that early T2 prolongation occurred at reversible disease stages [8]. This study also demonstrated that T1 progressively increases after 10 weeks of doxorubicin and is coincided with a progressive ejection fraction decline [8].

Our study in humans confirms and extends the knowledge about the value of T2 and T1 to detect chemotherapy-related myocardial injury. Interestingly, we found a more pronounced increase in T1 compared to T2 in our patients with chemotherapy. This finding is most likely related to the fact that we performed the first follow-up CMR 2 weeks after chemotherapy completion, which was given for 5 months, whereas Galán-Arriola et al performed weekly CMR [8]. We presume that we imaged the patients at a later time point of myocardial injury when T2 had already normalized, but T1 was still elevated. Similar to Galán-Arriola et al, we observed that the T1 increase was paralleled by a LV dysfunction quantified by strain analysis [8].

The CTRCD frequency of 20% after chemotherapy is well in line with a recent meta-analysis, which reported a cardiotoxicity frequency of 17% with the highest risk in the high-dose chemotherapy subgroup with 19.6% [16]. The occurrence of CTRCD after radiation is currently less well analyzed. Recent studies showed that left-sided radiation results in reduced myocardial strain by echocardiography [17, 18]. However, the incidence of CTRCD was not reported. Currently, several ongoing studies will analyze early detection and prediction of cardiotoxicity after radiation therapy for breast cancer and will provide more precise data about CTRCD [19, 20]. We observed a low frequency of CTRCD after radiation with 4% by using established criteria. The low frequency is potentially related to the low cardiac radiation dose of 2 ± 2 Gy, which was achieved by dedicated three-dimensional treatment plans including tangential beam orientation and deep inspiration breath-hold technique.

Our study showed that T1 and GCS at FU1 were the best single parameters to predict CTRCD at FU2 with good AUCs of 0.712. T1 was characterized by excellent sensitivity of 100%, but low specificity of 44%. Conversely, GCS resulted in a balanced sensitivity of 67% and specificity of 75%. Interestingly, blood parameters of myocardial injury such as high sensitive troponin T and NT-proBNP had lower AUCs compared to T1 and GCS, indicating that the increase of these laboratory parameters is an epiphenomenon of chemotherapy and radiation, but they have limited value to identify CTRCD. This is in line with a recent meta-analysis on the use of troponins and NT-proBNP for cardiotoxicity prediction after chemotherapy reporting similar sensitivity of 69%, but higher specificity of 87% for troponins and limited predictive value of NT-proBNP [16]. Interestingly, T2 had the lowest AUC of 0.513 to predict CTRCD. In patients with an acute myocardial injury such as myocarditis or myocardial infarction, T1 and T2 are equally good in identifying disease [21, 22]. In contrast, the current data indicated that T2 is of limited value to identify CTRCD. Altaha et al recently reported a significant overlap of temporal changes in CMR mapping parameters between chemotherapy patients and healthy subjects, whereas T1 showed less overlap than T2 [15]. Similarly, we found an T1 and T2 overlap between patients with and without CTRCD. Thus, the low specificity of T1 and low AUC of T2 might be explained by their moderate increase at the chosen time point following oncologic therapy as opposed to the more pronounced changes caused by myocarditis and myocardial infarction. It is possible, that imaging at a different time point during or after cancer therapy may result in a better performance of these parameters to predict CTRCD.

However, the combined use of increased T1 and reduced cardiac function by LVEF ≤ 60% at FU1 increased the diagnostic accuracy and AUC was 0.810. The combination of T1 and LVEF ≤ 60% resulted in balanced sensitivity (78%), specificity (84%), and accuracy (83%).

The sample size is relatively small. However, this prospective and consecutive study adds to the body of evidence on cardiotoxic effects of cancer therapy in humans and evaluates the predictive value of CMR. Second, our findings are confined to the chemotherapy and radiotherapy applied in this study.